GlassScriptPhysician profile
Henry Ngo
NPI 1518954627
$5,668.16
in general payments reported to CMS, 2019-2025
32 companies · $124 in 2025
The $124 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,415 · 2020: $1,110 · 2021: $1,443 · 2022: $1,441 · 2023: $136 · 2025: $124.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $259.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $259.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,086.11 | 2019-2023 | Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $633.04 | 2019-2023 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $587.94 | 2019-2023 | Breztri |
| Sanofi-Aventis U.S. LLC | $446.40 | 2019-2022 | |
| Glaxosmithkline, LLC. | $371.84 | 2019-2023 | Trelegy Ellipta |
| Pfizer INC. | $361.88 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $296.63 | 2019-2022 | |
| Lilly USA, LLC | $292.65 | 2019-2023 | Mounjaro |
| Astellas Pharma US INC | $220.63 | 2019-2022 | |
| Amgen INC. | $211.53 | 2019-2022 | |
| Abbott Laboratories | $190.24 | 2019-2023 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $149.30 | 2021-2023 | |
| Abbvie INC. | $128.24 | 2021-2023 | |
| Sanofi Pasteur INC. | $123.66 | 2025 | |
| Merck Sharp & Dohme LLC | $98.38 | 2019-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $82.63 | 2021-2022 | |
| Allergan, INC. | $51.84 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $46.46 | 2021 | |
| Amarin Pharma, INC. | $44.64 | 2019 | |
| Vivus LLC | $33.42 | 2019 | |
| Novartis Pharmaceuticals Corporation | $31.84 | 2019-2020 | |
| Zyla Life Sciences, INC. | $26.47 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $20.90 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $19.92 | 2022 | |
| Xeris Pharmaceuticals, INC. | $17.05 | 2022 | |
| Alexion Pharmaceuticals, INC. | $16.20 | 2019 | |
| Philips North America LLC | $14.55 | 2022 | |
| Alvogen INC | $13.62 | 2022 | |
| Dexcom, INC. | $13.27 | 2021 | |
| Radius Health, INC. | $13.15 | 2019 | |
| Eisai INC. | $12.38 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $11.35 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Henry Ngo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.